FBXW7 mutations in melanoma and a new therapeutic Paradigm

Journal of the National Cancer Institute

Volumn 106, Issue 6, 2014, Pages

  Aydin, Iraz T ^a,b   Melamed, Rachel D ^a,c   Adams, Sarah J ^a,b   Castillo Martin, Mireia ^b   Demir, Ahu ^a,b   Bryk, Diana ^a,b   Brunner, Georg ^d,e   Cordon Cardo, Carlos ^b   Osman, Iman ^f   Rabadan, Raul ^a,c   Celebi, Julide Tok ^a,b  

^a Department of Dermatology ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e Department of Cancer Research Skin Cancer Center Hornheide   (Germany)

^f NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH1 RECEPTOR; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; EXOME; FBXW7 GENE; FEMALE; GENE IDENTIFICATION; GENE INACTIVATION; GENE PRODUCT; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA CELL LINE; METASTATIC MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; UPREGULATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOHISTOCHEMISTRY; MELANOMA; MUTATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; F-BOX PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84905180212     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju107     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445(7130):851-857.
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
4. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-263.
5. Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44(9):1006-1014.
6. Wang Z, Inuzuka H, Zhong J, et al. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012;586(10):1409-1418.
7. Bai C, Sen P, Hofmann K, et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell. 1996;86(2):263-274.
8. Zhang W, Koepp DM. Fbw7 isoform interaction contributes to cyclin E proteolysis. Mol Cancer Res. 2006;4(12):935-943.
9. Hao B, Oehlmann S, Sowa ME, Harper JW, Pavletich NP. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell. 2007;26(1):131-143.
10. Orlicky S, Tang X, Willems A, Tyers M, Sicheri F. Structural basis for phos-phodependent substrate selection and orientation by the SCFCdc4 ubiqui-tin ligase. Cell. 2003;112(2):243-256.
11. Oberg C, Li J, Pauley A, et al. The Notch intracellular domain is ubiquit-inated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem. 2001;276(38):35847-35853.
12. Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001;294(5540):173-177.
13. Welcker M, Orian A, Jin J, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA. 2004;101(24):9085-9090.
14. Tsunematsu R, Nakayama K, Oike Y, et al. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem. 2004;279(10):9417-9423.
15. Frattini V, Trifonov V, Chan JM, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet. 2013;45(10):1141-1149.
16. Trifonov V, Pasqualucci L, Tiacci E, Falini B, Rabadan R. SAVI: a statistical algorithm for variant frequency identification. BMC Systems Biology. 2013;7(Suppl 2):1-11.
17. Brown G, Wallin C, Tatusova T, Pruitt K, Maglott D. Gene Help: Integrated Access to Genes of Genomes in the Reference Sequence Collection. Bethesda, MD: National Center for Biotechnology Information; 2005-2006.
18. Shrager JTJ, Travers M. Cancer commons: biomedicine in the Internet age. In: Elkins S, Hupcey M, Williams A, eds. Collaborative Computational Technologies for Biomedical Research. Hoboken, NJ: John Wiley & Sons, Inc; 2010.
19. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppres-sive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 2008;105(52):20852-20857.
20. Akhoondi S, Sun D, von der Lehr N, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007;67(19):9006-9012.
21. Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiqui-tin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007;204(8):1825-1835.
22. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
23. Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485(7399):502-506.
24. Nikolaev SI, Rimoldi D, Iseli C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 2012;44(2):133-139.
25. Stark MS, Woods SL, Gartside MG, et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet. 2012;44(2):165-169.
26. Prickett TD, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet. 2009;41(10):1127- 1132.
27. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011;43(5):442-446.
28. Prickett TD, Wei X, Cardenas-Navia I, et al. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet. 2011;43(11):1119-1126.
29. Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464(7291):1052-1057.
30. Bales ES, Dietrich C, Bandyopadhyay D, et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol. 1999;113(6):1039-1046.
31. Balint K, Xiao M, Pinnix CC, et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest. 2005;115(11):3166-3176.
32. Pinnix CC, Lee JT, Liu ZJ, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009;69(13):5312-5320.